Securing Supply Chains Amid Global Tensions
India's pharmaceutical industry faces a critical challenge: building stronger supply chains and protecting its large export market from growing global uncertainty. Commerce Secretary Rajesh Agarwal stressed the need to cut reliance on imported raw materials and active pharmaceutical ingredients (APIs) "as much as possible," even if complete substitution isn't feasible. This essential defensive move comes as regional conflicts raise shipping costs and threaten vital trade routes. The Nifty Pharma index shows investor concern, falling 3.2% last week and 5% last month, with technical signs pointing to short-term weakness.
Biosimilars Offer Growth, But API Costs Rise
While the focus is on reducing API imports, India's pharma sector is also seeing strong growth in higher-value areas like biosimilars. The Indian biosimilars market is expected to surge from about $184 million in 2026 to over $1 billion by 2035, driven by chronic diseases and the need for affordable biologics. This expanding segment offers future value, unlike the import-reliant API sector. China remains a top API producer and exporter, though India holds the most API Drug Master Files (DMFs) globally. However, China has outpaced India in new DMF filings for 2024, suggesting a shift in manufacturing. India's reliance on APIs and intermediates, many from China, means current geopolitical tensions not only risk export shipments but could also increase domestic manufacturing costs.
Geopolitical Shocks Threaten Exports and Valuations
The combination of global instability and higher shipping costs poses a significant threat to India's pharmaceutical exports. The conflict in West Asia has already doubled freight charges, adding $4,000-$8,000 per shipment and squeezing profit margins. Industry estimates suggest March exports to the Gulf Cooperation Council (GCC) and West Asia/North Africa (WANA) regions could lose between ₹2,500 crore and ₹5,000 crore if disruptions continue. These higher costs are particularly worrying for temperature-sensitive medicines and could undermine India's competitive pricing, especially for generic drugs. Despite strong financials for companies like Sun Pharmaceutical Industries and Torrent Pharmaceuticals, their stock valuations appear high. Sun Pharma trades at a P/E of about 37.99x, and Torrent at 58.5x, both well above the industry average. This leaves little room for earnings misses due to supply chain problems. The sector's overall P/E is around 31.6x, still reflecting high growth expectations.
Cautious Optimism for Future Growth
Despite current challenges, the future outlook for India's pharmaceutical sector remains broadly positive. Ratings agency ICRA maintains a "Stable" outlook, predicting revenue growth of 7-9% for fiscal year 2026, supported by strong domestic demand and gains in European markets. Overall industry earnings are expected to grow about 17% annually, showing resilience. For the sector to achieve its full potential, it must effectively manage current geopolitical risks, diversify sources for key inputs, and continue investing in high-growth areas like biosimilars to maintain long-term competitiveness.